Update on SAR studies toward new COX-1 selective inhibitors

Current Medicinal Chemistry

Volumn 22, Issue 37, 2015, Pages 4271-4292

  Vitale, Paola ^a   Scilimati, Antonio ^a   Perrone, Maria Grazia ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Arylpropanoic acids; Benzanilides; COX 2; Cyclooxygenase (COX) 1; Diarylheterocycles; NSAIDs; Stilbenes; Structure activity relationship(SAR)

Indexed keywords

ACRYLIC ACID DERIVATIVE; BIPHENYL DERIVATIVE; CHALCONE DERIVATIVE; CYCLOOXYGENASE 1 INHIBITOR; FURAN DERIVATIVE; INDENE DERIVATIVE; INDOLE DERIVATIVE; ISOTHIAZOLE DERIVATIVE; ISOXAZOLE DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENAZONE DERIVATIVE; PROPIONIC ACID DERIVATIVE; PYRAZOLE DERIVATIVE; PYRONE DERIVATIVE; THIAZOLE DERIVATIVE; CYCLOOXYGENASE 1; PROSTAGLANDIN SYNTHASE INHIBITOR;

ARTICLE; CHEMICAL MODIFICATION; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; HUMAN; NONHUMAN; STRUCTURE ACTIVITY RELATION; CHEMISTRY; DRUG DEVELOPMENT; METABOLISM; TRENDS;

CYCLOOXYGENASE 1; CYCLOOXYGENASE INHIBITORS; DRUG DISCOVERY; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84953775020     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867322666151029104717     Document Type: Article

References (34)

1. Perrone, M. G.; Scilimati, A.; Simone, L.; Vitale, P. Selective Cox-1 Inhibition: A therapeutic target to be reconsidered. Curr. Med. Chem., 2010, 17, 3769-3805.
2. Choi, S. H.; Aid, S.; Caracciolo, L.; Minami, S. S.; Niikura, T.; Matsuoka, Y.; Turner, R. S.; Mattson, M. P.; Bosetti, F. Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer's disease. J. Neurochem., 2013, 124, 59-68.
3. Zheng, X.; Oda, H.; Takamatsu, K.; Sugimoto, Y.; Tai, A.; Akaho, E.; Ali, H. I.; Oshiki, T.; Kakuta, H.; Sasaki, K. Analgesic agents without gastric damage: Design and synthesis of structurally simple benzenesulfonanilide-type cyclooxygenase-1-selective inhibitors. Bioorg. Med. Chem., 2007, 15, 1014-1021.
4. Kakuta, H.; Zheng, X.; Oda, H.; Harada, S.; Sugimoto, Y.; Sasaki, K.; Tai, A. Cyclooxygenase-1-selective inhibitors are attractive candidates for analgesics that do not cause gastric damage. Design and in vitro/in vivo evaluation of a benzamide-type cyclooxygenase-1 selective inhibitor. J. Med. Chem., 2008, 51, 2400-2411.
5. Kakuta, H.; Fukai, R.; Zheng, X.; Ohsawa, F.; Bamba, T.; Hirata, K.; Tai, A. Identification of urine metabolites of TFAP, a cyclooxygenase-1 inhibitor. Bioorg. Med. Chem. Lett., 2010, 20, 1840-1843.
6. Fukai, R.; Zheng, X.; Motoshima, K.; Kakuta, H. Significance and creation of novel cyclooxygenase-1 (COX-1) selective inhibitors. Yakugaku Zasshi, 2011, 131(3), 347-351.
7. Liu, W.-B; Zheng, S.-C; He, H.; Zhao, X.-M.; Dai, L.-X.; You, S.-L. Iridium-catalyzed regio- and enantioselective allylic of fluorobis (phenylsulfonyl) methane. Chem. Commun., 2009, 43, 6604-6606.
8. Su, H.; Xie, Y.; Liu, W.-B.; You, S.-L. Methylmonofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo. Bioorg. Med. Chem. Lett., 2011, 21 3578-3582.
9. Perrone, M. G.; Vitale, P.; Panella, A.; Tolomeo, A., Scilimati, A. Current and emerging applications of fluorine in medicinal chemistry. In: Fluorinated Pharmaceuticals: Advances in Medicinal Chemistry. Westwell, A. D., Ed. Future Science, London, UK, 2015.
10. Penning, T. D.; Talley, J. J.; Bertenshaw, S. R.; Carter, J. S.; Collins, P. W.; Docter, S.; Graneto, M. J.; Lee, L. F.; Malecha, J. W.; Miyashiro, J. M.; Rogers, R. S.; Rogier, D. J.; Yu, S. S.; Anderson, G. D.; Burton, E. G.; Cogburn, J. N.; Gregory, S. A.; Koboldt, C. M.; Perkins, W. E.; Seibert, K.; Veenhuizen, A. W.; Zhang, Y. Y.; Isakson, P. C. Synthesis and biological evaluation of the 1, 5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, Celecoxib). J. Med. Chem., 1997, 97, 1347-1365.
11. Perrone, M. G.; Vitale, P.; Malerba, P.; Altomare, A.; Rizzi, R.; Lavecchia, A.; Di Giovanni, C.; Novellino, E.; Scilimati, A. Diarylheterocycle core ring features effect in selective COX-1 inhibition. ChemMedChem, 2012, 7, 629-641.
12. Carradori, S.; Secci, D.; Bolasco, A.; De Monte, C.; Yáñez, M. Synthesis and selective inhibitory activity against human COX-1 of novel 1-(4-substituted-thiazol-2-yl)-3, 5-di (hetero) aryl-pyrazoline derivatives. Arch. Pharm., 2012, 345, 973-979.
13. Ergun, B. C.; Nunez, M. T.; Labeaga, L.; Ledo, F.; Darlington, J.; Bain, G.; Cakir, B.; Banoglu, E. Synthesis of 1, 5-diarylpyrazol-3-propanoic acids towards inhibition of cyclooxygenase-1/2 activity and 5-lipoxygenase-mediated LTB4 formation. Arzneimittel-Forschung, 2010, 60(8), 497-505.
14. Imanishi, J.; Morita, Y.; Yoshimi, E.; Kuroda, K.; Masunaga, T.; Yamagami, K.; Kuno, M.; Hamachi, E.; Aoki, S.; Takahashi, F.; Nakamura, K.; Miyata, S.; Ohkubo, Y.; Mutoh, S. Pharmacological profile of FK881(ASP6537), a novel potent and selective cyclooxygenase-1 inhibitor. Biochem. Pharmacol., 2011, 82, 746-754.
15. Perrone, M. G.; Vitale, P.; Panella, A.; Fortuna, C. G.; Scilimati, A. General role of the amino and methylsulfamoyl groups in selective cyclooxygenase (COX)-1 inhibition by 1, 4-diaryl-1, 2, 3-triazoles and validation of a predictive pharmacometric PLS model. Eur. J. Med Chem., 2015, 94, 252-264.
16. Vitale, P.; Scilimati, A. Five-membered ring heterocycles by reacting enolates with dipoles. Curr. Org. Chem., 2013, 17, 1986-2000.
17. Vitale, P.; Scilimati, A. Functional 3-arylisoxazoles and 3-aryl-2-isoxazolines from reaction of aryl nitrile oxides and enolates: synthesis and reactivity. Synthesis, 2013, 45, 2940-2948.
18. Amirhamzeh, A.; Vosoughi, M.; Shafiee, A.; Amini, M. Synthesis and docking study of diaryl-isothiazole and 1, 2, 3-thiadiazole derivatives as potential neuroprotective agents. Med. Chem. Res., 2013, 22, 1212-1223.
19. Di Nunno, L.; Vitale, P.; Scilimati, A.; Tacconelli, S.; Patrignani, P. Novel synthesis of 3, 4-diarylisoxazole analogues of valdecoxib: reversal cyclooxygenase-2 selectivity by sulfonamide group removal. J. Med. Chem., 2004, 47, 4881-4890.
20. Vitale, P.; Tacconelli, S.; Perrone, M. G.; Malerba, P.; Simone, L.; Scilimati, A.; Lavecchia, A.; Dovizio, M.; Marcantoni, E.; Bruno, A.; Patrignani, P. Synthesis, pharmacological characterization, and docking analysis of a novel family of diarylisoxazoles as highly selective cyclooxygenase-1 (COX-1) inhibitors. J. Med. Chem., 2013, 56, 4277-4299.
21. Vitale, P.; Perrone, M. G.; Malerba, P.; Lavecchia, A.; Scilimati, A. Selective COX-1 inhibition as a target of theranostic novel diarylisoxazoles. Eur. J. Med. Chem., 2014, 74, 606-618.
22. Perrone, M. G.; Malerba, P.; Uddin, M. J.; Vitale, P.; Panella, A.; Crews, B. C.; Daniel, C. K.; Ghebreselasie, K.; Nickels, M.; Tantawy, M. N.; Manning, H. C.; Marnett, L. J.; Scilimati, A. PET radiotracer [18F]-P6 selectively targeting COX-1 as a novel biomarker in ovarian cancer: Preliminary investigation. Eur. J. Med. Chem., 2014, 80, 562-568.
23. Uddin, M. J.; Elleman, A. V.; Ghebreselasie, K.; Daniel, C. K.; Crews, B. C.; Nance, K. D.; Huda, T.; Marnett, L. J. Design of Fluorine-Containing 3, 4-Diarylfuran-2-(5H) - ones as Selective COX-1 Inhibitors. ACS Med. Chem. Lett., 2014, 5(11), 1254-1258.
24. Chu, X.-P.; Zhou, Q.-F.; Zhao, S.; Ge, F.-F.; Fu, M.; Chen, J.-P.; Lu, T. Synthesis and biological evaluation of 3-amino-2-pyrones as selective cyclooxygenase-1 (COX-1) inhibitors. Chin. Chem. Lett., 2013, 24, 120-122.
25. (a) Praveen Rao, P. N.; Amini, M.; Li, H.; Habeeb, A. G.; Knaus, E. E. Design, synthesis, and biological evaluation of 6-substituted-3-(4-methanesulfonylphenyl)-4-phenylpyran-2-ones: a novel class of diarylheterocyclic selective cyclooxygenase-2 inhibitors, J. Med. Chem., 2003, 46, 4872-4882;
26. (b) Rao, P. P. N.; Uddin, M. J.; Knaus, E. E. Design, synthesis, and structure. activity relationship studies of 3, 4, 6-triphenylpyran-2-ones as selective cyclooxygenase-2 inhibitors. J. Med. Chem., 2004, 47, 3972-3990.
27. Hwang, S. H.; Wecksler, A. T.; Wagner, K.; Hammock, B. D. Rationally designed multitarget agents against inflammation and pain. Curr. Med. Chem., 2013, 20, 1783-1799.
28. Lai, Y.; Ma, L.; Huang, W.; Yu, X.; Zhang, Y.; Ji, H.; Tian, J. Synthesis and biological evaluation of 3-[4-(amino/methylsulfonyl) phenyl]methylene-indolin-2-one derivatives as novel COX-1/2 and 5-LOX inhibitors. Bioorg. Med. Chem. Lett., 2010, 20, 7349.7353.
29. Moore, P. F.; Larson, D. L.; Otterness, I. G.; Weissman, A.; Kadin, S. B.; Sweeney, F. J.; Eskara, J. D.; Nagahisa, A.; Sakakibara, M.; Carty, T. J. Tenidap, a structurally novel drug for the treatment of arthritis: antiinflammatory and analgesic properties. Inflamm. Res., 1996, 45, 54-61.
30. Liedtke, A. J.; Crews, B. C.; Daniel, C. M.; Blobaum, A. L.; Kingsley, P. J.; Ghebreselasie, K.; Marnett, L. J. Cyclooxygenase-1-selective inhibitors based on the (E)-2'-desmethylsulindac sulfide scaffold. J. Med. Chem., 2012, 55, 2287.2300.
31. Wu, C.-M.; Lin, K.-W.; Teng, C.-H.; Huang, A.-M.; Chen, Y.-C.; Yen, M.-H.; Wu, W.-B.; Pu, Y.-S.; Lin, C.-N. Chalcone derivatives inhibit human platelet aggregation and inhibit growth in human bladder cancer cells. Biol. Pharm. Bull., 2014, 37, 1191-1198.
32. Pontiki, E.; Hadjipavlou-Litina, D.; Litinas, K.; Nicolotti, O.; Carotti, A. Design, synthesis and pharmacobiological evaluation of novel acrylic acid derivatives acting as lipoxygenase and cyclooxygenase-1 inhibitors with antioxidant and anti-inflammatory activities. Eur. J. Med. Chem., 2011, 46(1), 191-200.
33. Chakrabarty, M.; Mukherji, A.; Karmakar, S.; Mukherjee, R.; Nagai, K.; Geronikaki, A.; Eleni, P. An expedient synthesis of novel 2-substituted thiazolo[4, 5-f]isoquinolines/quinolines and benzo[1, 2-d:4, 3-d]bisthiazoles and their potential as inhibitors of COX-1 and COX-2. Arkivoc, 2010, (xi), 265-290.
34. De Vivo, M.; Scarpelli, R.; Cavalli, A.; Migliore, M.; Piomelli, D.; Habrant, D.; Favia, A. D. Multitarget FAAH and COX inhibitors and therapeutical uses thereof. WO 2014/023643 A1, 2014.